American journal of clinical oncology
A Real-World, Propensity-Matched Analysis of Second-Line FOLFIRI-Ramucirumab Versus Ramucirumab-Paclitaxel in Patients With Advanced Upper Gastrointestinal Cancers.
Jonathan M Hyak, Peifeng Ruan, Amy L Jones, Nilesh Verma, Victoria Chung, Udhayvir S Grewal, Deepak Vadehra, Nicholas Hornstein, Sam C Wang, Matthew R Porembka, Shahed Badiyan, Nina N Sanford, Syed Kazmi, Timothy J Brown
Published: 202510.1097/COC.0000000000001283
Abstract
OBJECTIVES: There is an urgent need for effective second line treatments for advanced upper gastrointestinal (UGI) cancers. Ramucirumab and paclitaxel (Ram-Pac) has long been the standard therapy; however, this regimen is often complicated by cumulat…
Preview only. Read the full abstract at the source